Sinovac Biotech Ltd.

SINOVAC Posts 12.9% Revenue Growth on Overseas Expansion, Advances Late-Stage Vaccine Pipeline

- SINOVAC reported first-half 2026 sales of $147.1 million, up 12.9% year-over-year, driven by an 82.3% surge in overseas revenue that now accounts for 45.2% of total sales. - The company's rabies vaccine (PVRV-SF) received NMPA marketing approval on August 4, 2026, and the NDA for its bivalent enterovirus vaccine (HFMD2) was accepted for priority review. - Net loss attributable to common shareholders widened to $60.2 million, or $0.84 per share, from $21.7 million in the prior-year period. - Five late-stage vaccine candidates, including PCV13 and HFMD2, are advancing toward commercialization, with a PCV13 NDA submission expected in the third quarter of 2026.